Protagonist therapeutics, inc. (PTGX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
License and collaboration revenue - related party

3,647

2,719

4,141

-8,189

1,560

-

6,117

11,674

-

-

-

-

-

-

-

-

-

-

-

License and collaboration revenue - related party

-

-

-

-

-

-

-

-

10,781

-

8,781

-

-

-

-

-

-

-

-

License and collaboration revenue - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Operating expenses:
Research and development

18,768

15,911

17,293

19,355

12,444

14,249

12,145

17,735

15,368

11,724

11,168

12,007

11,282

8,823

5,561

5,696

5,625

3,158

2,297

General and administrative

4,576

4,107

4,015

3,863

3,764

3,516

3,361

3,178

3,642

3,071

2,593

3,124

2,991

2,574

1,577

1,395

1,415

863

786

Total operating expenses

23,344

20,018

21,308

23,218

16,208

17,765

15,506

20,913

19,010

14,795

13,761

15,131

14,273

11,397

7,138

7,091

7,040

4,021

3,083

Loss from operations

-19,697

-17,299

-17,167

-31,407

-14,648

-15,412

-9,389

-9,239

-8,229

-3,513

-4,980

-15,131

-14,273

-11,397

-7,138

-7,091

-7,040

-4,021

-3,083

Interest income

526

822

656

604

731

768

654

576

568

469

155

152

172

149

54

27

12

1

-

Interest expense

243

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of redeemable convertible preferred stock tranche and warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,719

-571

136

Other expense, net

-490

-

-

-

-3

-

-

-

-

-

-

-

-

-

0

-34

-

-

-

Loss before income tax expense

-19,904

-16,644

-16,511

-30,803

-13,920

-14,664

-8,735

-8,663

-7,661

-

-

-

-

-

-

-

-

-

-

Income tax expense

176

848

-102

-1,629

183

-799

0

0

0

-

-

-

-

-

-

-

-

-

-

Net loss

-20,080

-17,501

-16,409

-29,174

-14,103

-13,865

-8,735

-8,663

-7,661

-3,052

-4,825

-14,979

-14,101

-11,248

-7,084

-7,098

-11,747

-3,449

-3,219

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,248

-7,377

-7,323

-11,787

-3,485

-3,219

Net loss per share, basic and diluted

-0.72

-0.61

-0.61

-1.18

-0.58

-0.59

-0.38

-0.41

-0.36

-0.07

-0.29

-0.89

-0.84

55.10

-0.87

-19.07

-40.96

-12.79

-13.78

Weighted-average shares used to compute net loss per share, basic and diluted

27,703

27,658

26,956

24,662

24,297

24,226

22,912

21,207

21,112

20,224

16,911

16,875

16,766

16,852

8,483

383

287

272

233